Astex, J&J sign $500 million cancer drug research deal

06/10/2008 | Reuters

U.K.-based Astex Therapeutics announced it has signed a cancer drug research deal that gives Johnson & Johnson's Janssen unit worldwide rights to develop and commercialize compounds arising from Astex's FGFR inhibitor program. The agreement, which could be worth more than $500 million in milestone payments, also creates a drug discovery program for two additional cancer therapy targets.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Affairs Specialist
Becton Dickinson
Franklin Lakes, NJ
Customer Service Director
Minneapolis, MN
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Behavioral Health Operations Director
Minneapolis, MN
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID